|
| Study ID | Sample | Age |
Diagnosis standard |
Intervention |
Control | Course | Outcome measure |
| (M/F) | (yrs) | (week) |
|
|
F.M. Liu and C. F. Liu, 2009 [41] | 60
T: 21/10;
C: 20/9 | 41 to 76 (T/C not reported) | 1999 WHO-ISH GMH | TXL + C | Amlodipine (5 mg qd) | 8
(3 pills/time, tid) | BP;
Adverse event |
Li et al.
2003 [42] | 86
T: 44; C: 42
M/F: 54/32 | 60 to 75 (T/C not reported) | 1999 WHO-ISH GMH | TXL + C | Nifedipine controlled released tablets (30 mg qd) | 12
(3 pills /time, tid) | BP;
Adverse event |
Lu et al.
2012 [43] | 94
T: 48; C: 46
M/F: 59/35 | . (T/C not reported) | 1999 WHO-ISH GMH | TXL + C | Nifedipine controlled released tablets (30 mg qd) | 24 (0.38 g/pill, 4 pills/time, tid) | BP |
| Xie, 2006 [44] | 60
T: 18/12
C: 20/10 | T:
C: | Hypertension diagnostic criteria (unclear) | TXL + C | Benazepril Hydrochloride tablets (10 mg qd) | 24
(0.38 g/pill, 4 pills/time, tid) | BP |
Wei and Chen,
2009 [45] | 93
T: 18/25
C: 21/29 | T:
C: | Chinese Guidelines for the Management of Hypertension-2004 (CGMH-2004) | TXL + C | Western medicine | 24
(4 pills/time, tid) | BP |
Xu et al.
2009 [46] | 100
T: 36/14
C: 38/12 | 40–79
(T/C not reported) | Chinese Guidelines for the Management of Hypertension-2004 (CGMH-2004) | TXL + C | Western medicine | 24 (3 pills/time, bid) | BP
|
| Zhao and Cheng, 2010 [47] | 90
T: 26/19
C: 33/12
| T:
C: | 1999 WHO-ISH GMH | TXL + C | Irbesartan tablets (150 mg qd) | 24 (3 pills/time, tid) | BP;
Adverse event
|
Xu et al.
2007 [48] | 72
T: 36; C: 36
M/F: 59/35 | (T/C not reported) | 1999 WHO-ISH GMH | TXL + C | Western medicine | 8 (3 pills/time, tid) | BP
|
| Zhu, 2011 [49] | 61
T: 30; C: 31
(M/F not reported) | 45–70
(T/C not reported) | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL + C | Felodipine sustained release tablets (2.5–5.0 mg) | 6 (3 pills/time, tid) | BP
|
|
Rao, 2009 [50] | 147
T: 41/33
C: 39/34 | T:
C: | Chinese Guidelines for the Management of Hypertension-2000 (CGMH-2000) | TXL + C | Nifedipine controlled release tablets (10 mg bid); Captopril (25 mg tid) | 12 (0.26 g/pill, 4 pills/time, tid) | BP;
Adverse event
|
| Mo et al. 2009 [51] | 240
T: 79/41
C: 76/44 | T:
C: | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL + C | Fosinopril sodium tablets (10 mg qd) | 12 (0.26 g/pill, 3 pills/time, tid) | BP;
Adverse event |
Xu,
2005 [52] | 52
T: 19/8
C: 18/7 | T: 40–76
C: 41–76 | 1999 WHO-ISH GMH | TXL + C | Amlodipine (5 mg qd) | 8 (3 pills/time, tid) | BP;
Adverse event |
Li et al.
2012 [53] | 81
T: 40
C: 41
M: 81 | 65 to 80 (T/C not reported) | The management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) 2007 | TXL + C | Candesartan (8 mg qd) | 12 (3 pills/time, tid) | BP |
Cheng et al.
2011 [54] | 108
T: 39/29
C: 23/17 | T:
C: | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL + C |
Losartan (50–100 mg qd) | 4 (3 pills/time, tid) | BP |
| Wang, 2011 [55] | 194
T: 57/40
C: 58/39 | T: 42–74
C: 41–73 | 1999 WHO-ISH GMH | TXL + C | Nifedipine sustained release tablets (10 mg bid) | 4 (3 pills/time, bid) | BP;
Adverse event |
Chen et al.
2011 [56] | 178
T: 49/40
C: 47/42 | T:
C: | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL + C | Valsartan capsules (80–160 mg qd) | 24 (4 pills/time, tid) | BP;
Adverse event
|
Liao,
2006 [57] | 80
T: 22/18
C: 24/16 | T:
C: | 1999 WHO-ISH GMH | TXL + C | Western medicine | 16 (3 pills/time, tid) | BP |
Zhang,
2011 [58] | 60
T: 30
C: 30
(M/F not reported) | (T/C not reported) | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL + C | Valsartan (160 mg qd) | 8 (3 pills/time, tid) | BP |
| Yan and He, 2007 [59] | 102
T: 32/20
C: 29/21 | T: 40–74
C: 41–75 | 1999 WHO-ISH GMH | TXL + C | Amlodipine Benzenesulfonate tablets (5 mg qd)
| 4 (0.38 g/pill, 3 pills/time, bid) | BP;
Adverse event
|
| Jiang, 2011 [60] | 76
T: 26/12
C: 24/14 | T:
C: | 1999 WHO-ISH GMH | TXL + C | Benazepril (10 mg qd)
| 24 (3 pills/time, tid) | BP |
Wang et al.
2004 [61] | 193
T: 58/39
C: 57/39 | T: 41–73
C: 40–73 | 1999 WHO-ISH GMH | TXL + C | Nifedipine sustained release tablets (10 mg bid) | 4 (0.38 g/pill, 3 pills/time, bid) | BP;
Adverse event
|
Lu and Zha,
2005 [62] | 77
M/F: 37/40
(T/C not reported) | | 1999 WHO-ISH GMH | TXL + C | Western medicine | 8 (4 pills/time, tid) | BP |
| Hu, 2013 [63] | 76
T: 28/15
C: 19/14 | T: 39–73
C: 34–65 | Hypertension diagnostic criteria (unclear) | TXL + C | Enalapril (2.5 mg bid) | 52 (2–4 pills/time, tid) | BP;
Adverse event |
| Lu and Zhou, 2007 [64] | 45
T: 23
C: 22
M/F: 25/20
(T/C not reported) |
(T/C not reported) | Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005) | TXL | Placebo | 6 (3 pills/time, tid) | BP;
Adverse event
|
Zhao et al.
2007 [65] | 60
T: 30
C: 30
M/F: 34/26
(T/C not reported) | 55–75
(T/C not reported) | Hypertension diagnostic criteria (unclear) | TXL | Captopril (50 mg bid) | 4 (0.38 g/pill, 4 pills/time, bid) | BP |
|
